Table 3.

Select Adverse Events^*

AE Category	Treatment Group	0	1	2	3	4	5	Total	% Grade 3 or worse
Neutrophils/AGC††	−E −G	75	21	82	314	633	0	1125	84
	−E +G	12	1	11	55	232	0	311	92
	+E −G	4	4	16	52	165	0	241	90
	+E +G	6	1	7	47	126	0	187	92
Hemoglobin††	−E −G	110	424	482	97	12	0	1125	10
	−E +G	16	78	165	49	3	0	311	17
	+E −G	3	41	156	36	5	0	241	17
	+E +G	3	17	117	44	6	0	187	27
Febrile Neutropenia††	−E −G	1099	0	0	23	3	0	1125	2
	−E +G	268	0	0	40	3	0	311	14
	+E −G	234	0	0	6	1	0	241	3
	+E +G	167	0	0	17	3	0	187	11
Venous TE†	−E −G	1115	0	1	4	5	0	1125	1
	−E +G	310	0	0	0	1	0	311	< 1
	+E −G	237	0	1	2	1	0	241	1
	+E +G	181	0	0	1	5	0	187	3
Other TE	−E −G	1047	0	12	32	32	2	1125	6
	−E +G	292	1	3	9	6	0	311	5
	+E −G	262	0	1	9	5	0	241	6
	+E +G	170	1	4	7	5	0	187	6

^*Common Terminology Criteria for Adverse Events version 3.0. Onset of adverse event between start of study treatment and 30 days after date of last cycle of treatment.

^†p < 0.05,

^††p <0.001 for a two-sided exact test of the hypothesis that the incidence of a grade 3 or higher adverse event is independent of the treatment group.